Macitentan attenuates cardiovascular remodelling in infant rats with chronic lung disease

Baumann, Philipp and Greco, Francesco and Wiegert, Susanne and Wellmann, Sven and Pellegrini, Giovanni and Cannizzaro, Vincenzo (2022) Macitentan attenuates cardiovascular remodelling in infant rats with chronic lung disease. JOURNAL OF TRANSLATIONAL MEDICINE, 20 (1): 77. ISSN , 1479-5876

Full text not available from this repository. (Request a copy)

Abstract

Background Cardiovascular impairment contributes to increased mortality in preterm infants with chronic lung disease. Macitentan, an endothelin-1 receptor antagonist, has the potential to attenuate pulmonary and cardiovascular remodelling. Methods In a prospective randomized placebo-controlled intervention trial, Sprague-Dawley rats were exposed to 0.21 or 1.0 fraction of inspired oxygen (FiO(2)) for 19 postnatal days. Rats were treated via gavage with placebo or macitentan from days of life 5 to 19. Alveoli, pulmonary vessels, alpha-smooth muscle actin content in pulmonary arterioles, size of cardiomyocytes, right to left ventricular wall diameter ratio, and endothelin-1 plasma concentrations were assessed. Results FiO(2) 1.0 induced typical features of chronic lung disease with significant alveolar enlargement (p = 0.012), alveolar (p = 0.048) and pulmonary vessel rarefaction (p = 0.024), higher alpha-smooth muscle actin content in pulmonary arterioles (p = 0.009), higher right to left ventricular wall diameter ratio (p = 0.02), and larger cardiomyocyte cross-sectional area (p < 0.001). Macitentan treatment significantly increased pulmonary vessel count (p = 0.004) and decreased right to left ventricular wall diameter ratios (p = 0.002). Endothelin-1 plasma concentrations were higher compared to placebo (p = 0.015). Alveolar number and size, alpha-smooth muscle actin, and the cardiomyocyte cross-sectional area remained unchanged (all p > 0.05). Conclusion The endothelin-1 receptor antagonist macitentan attenuated cardiovascular remodelling in an infant rat model for preterm chronic lung disease. This study underscores the potential of macitentan to reduce cardiovascular morbidity in preterm infants with chronic lung disease.

Item Type: Article
Uncontrolled Keywords: BRONCHOPULMONARY DYSPLASIA; RESPIRATORY-DISTRESS; PULMONARY-HYPERTENSION; PRETERM INFANTS; ENDOTHELIN-1; OUTCOMES; ANGIOGENESIS; MODEL; Chronic lung disease; Endothelin receptor blockers; Preterm; Rats; Infants; Bronchopulmonary dysplasia
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Kinder- und Jugendmedizin
Depositing User: Dr. Gernot Deinzer
Date Deposited: 27 Feb 2024 09:48
Last Modified: 27 Feb 2024 09:48
URI: https://pred.uni-regensburg.de/id/eprint/58085

Actions (login required)

View Item View Item